Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| bioAffinity Technologies, Inc.BIAF · Entity 8368 | Secretary, EVP, Gen. Counsel | January 10, 2025 | January 14, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
bioAffinity Technologies, Inc.
Report date January 10, 2025 · Filed January 14, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 54,765 |
Reported balance
After 2025-01-10 transaction · row 1
1 source rowRow 1 · 2025-01-10 · Grant · Acquired 8,641 · Balance 54,765 F1: Grant of restricted shares of common stock that vest pro rata on a monthly basis for 12 months commencing on February 10, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of restricted shares of common stock that vest pro rata on a monthly basis for 12 months commencing on February 10, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 10, 2025 Filed Jan 14, 2025 21:15 UTC | bioAffinity Technologies, Inc. BIAF · Entity 8368 | GrantCommon Stock | 8,641 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-25-002147 · ownership.xml · nonDerivative · entry 1 Zannes Timothy P · CIK 0001947564 · Secretary, EVP, Gen. Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,765 F1 · shares: Grant of restricted shares of common stock that vest pro rata on a monthly basis for 12 months commencing on February 10, 2025. Read SEC document |
| April 04, 2024 Filed Apr 24, 2024 20:00 UTC | bioAffinity Technologies, Inc. BIAF · Entity 8368 | Exercise / conversionStock Option (right to buy) · Derivative | 64,848 | $0.00 Strike: $1.16 | $0.00 |
DisclosureSEC source: 0001493152-24-015790 · ownership.xml · derivative · entry 3 Zannes Timothy P · CIK 0001947564 · Secretary, EVP, Gen. Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 64,848 shares Expires 2024-04-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option vested in 7 equal monthly installments beginning on April 28, 2014. Read SEC document |
| April 04, 2024 Filed Apr 24, 2024 20:00 UTC | bioAffinity Technologies, Inc. BIAF · Entity 8368 | Tax withholdingCommon Stock | 29,031 | $2.58 | $74,899.98 |
DisclosureSEC source: 0001493152-24-015790 · ownership.xml · nonDerivative · entry 2 Zannes Timothy P · CIK 0001947564 · Secretary, EVP, Gen. Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,124 F1 · kind: Represents shares withheld to cover the exercise price of the options exercised. Read SEC document |
| April 04, 2024 Filed Apr 24, 2024 20:00 UTC | bioAffinity Technologies, Inc. BIAF · Entity 8368 | Exercise / conversionCommon Stock | 64,848 | $1.16 | $75,223.68 |
DisclosureSEC source: 0001493152-24-015790 · ownership.xml · nonDerivative · entry 1 Zannes Timothy P · CIK 0001947564 · Secretary, EVP, Gen. Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,155 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 31, 2024 Filed Feb 2, 2024 21:25 UTC | bioAffinity Technologies, Inc. BIAF · Entity 8368 | GrantCommon Stock | 6,688 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-24-004768 · ownership.xml · nonDerivative · entry 1 Zannes Timothy P · CIK 0001947564 · Secretary, EVP, Gen. Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,307 F1 · shares: Grant of restricted shares, which shares will vest pro rata on a monthly basis for 12 months commencing on February 29, 2024. Read SEC document |
| November 17, 2022 Filed Dec 5, 2022 21:29 UTC | bioAffinity Technologies, Inc. BIAF · Entity 8368 | GrantCommon Stock, par value $0.007 | 3,619 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-22-034472 · ownership.xml · nonDerivative · entry 1 Zannes Timothy P · CIK 0001947564 · Secretary, EVP, Gen. Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,619 F1 · kind: Represents a grant from bioAffinity Technologies, Inc. (the "Issuer") to Mr. Zannes of 3,619 restricted shares of the Issuer's common stock, par value $0.007 (the "Common Stock"), on November 17, 2022 under the Issuer's 2014 Equity Incentive Plan. The restricted stock will begin vesting on December 17, 2022 in 12 monthly installments, the first 11 of which will be of 301 shares of Common Stock and the last of which will be of the remaining 308 shares of Common Stock, subject to Mr. Zannes's continuous service to the Issuer through each vesting date. F1 · shares: Represents a grant from bioAffinity Technologies, Inc. (the "Issuer") to Mr. Zannes of 3,619 restricted shares of the Issuer's common stock, par value $0.007 (the "Common Stock"), on November 17, 2022 under the Issuer's 2014 Equity Incentive Plan. The restricted stock will begin vesting on December 17, 2022 in 12 monthly installments, the first 11 of which will be of 301 shares of Common Stock and the last of which will be of the remaining 308 shares of Common Stock, subject to Mr. Zannes's continuous service to the Issuer through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.